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aneurysm suharachnoid hemorrhage vasospasm thrombolytic therapy 9 fibrinolytic therapy 9 tissue plasminogen activator W 'H1LE the etiology and pathophysiology of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH) remains controversial, it is generally accepted that spasmogenic metabolites derived from the degradation of red blood cells during clot lysis play an important role. Recent studies from a number of laboratories have demonstrated that intracisternal fibrinolytic therapy can markedly enhance the clearance of blood from the subarachnoid spaces and reduce the severity of delayed cerebral vasospasm) -5'2j The most promising of these agents for use in man appears to be recombinant tissue plasminogen activator (rt-PA).
This study was undertaken to evaluate the safety and possible efficacy of intracisternal fibrinolytic therapy with rt-PA for the prevention of delayed cerebral vasospasm in patients with aneurysmal SAH. Data from serial tissue plasminogen activator (t-PA) measurements in ventricular and cisternal cerebrospinal fluid (CSF) were collected to help guide decisions about appropriate dosage regimens for future clinical trials.
Clinical Material and Methods
This study was conducted in accordance with all published guidelines of the United States Department of Health and Human Services, the National Institutes Table 3 ).'~ Vasospasm graded according to vessel luminal narrowing: severe = > 50% narrowing; moderate = 30% to 50% narrowing; mild = < 30% narrowing.
Clinical summary
of Health (NIH), and the Food and Drug Administration (an IND number for this protocol is on file in the Investigator's Office). 
Patient Population
Ten patients were enrolled in this protocol. Their clinical characteristics are summarized in Table 1 . Patients ranged from 23 to 83 years of age (mean 52 years). All patients were admitted within 48 hours of SAH and were classified in clinical Grade III or Grade IV according to Hunt and Hess? Computerized tomography (CT) on admission demonstrated thick layers of blood in the major cisterns and fissures (Group 3 SAH according to the Fisher CT grading scale 6) in all patients. Nine patients had aneurysms in the anterior circulation (five arising from the anterior communicating artery and four from the posterior communicating artery), and one patient had a posterior inferior cerebellar artery aneurysm. Because the level of consciousness was depressed in all patients, informed consent for participation in the protocol was obtained from the patients' legal guardian or nearest relative.
Patients were excluded from the study if they had abnormal coagulation parameters, evidence of active internal bleeding, recent cerebral infarction (within 2 months), recent biopsy of internal organs (within 10 days), or a history of medical illness associated with the increased risk of hemorrhage including chronic renal or hepatic disease, inflammatory bowel disease, hemorrhagic retinopathy, or serious gastrointestinal bleeding. Patients were also excluded if they were pregnant or if angiography revealed an intracranial vascular malformation. The presence of unclipped intracranial aneurysms was considered an absolute contraindication.
Treatment and Evaluation
The patients' medical and surgical management was dictated by the clinical course with the following restrictions. Ventriculostomy and surgery for clipping of the aneurysm had to be performed within 72 hours of hemorrhage. Routine care in this group of patients included treatment with prophylactic hypervolemic therapy including placement of a Swan-Ganz catheter. The pulmonary, artery diastolic pressure was maintained within 12 to 16 mm Hg using a combination of crystalloids (5% dextrose in lactated Ringer's solution and/or 0.9% NaC1 solution at 150 ml/hr) and Plasmanate (a preparation of human plasma protein fraction, 100 mi/hr as needed, when the pulmonary artery diastolic pressure was < 12 mm Hg). Patients were transfused to maintain the level of their hematocril between 30% and 35%. All patients were treated with nimodipine (60 mg every 4 hours) for 21 days after hemorrhage. Treatment with rt-PA was initiated only after successful clipping of all aneurysms.
In the first patient, 10 mg rt-PA was administered directly into the subarachnoid space just prior to dural closure. Because of postoperative oozing from the operative incision and ventricuiostomy site in this patient, the protocol was revised to insure greater safety. A small silicone lumbar drain catheter was left in the subarachnoid space (Fig. I) , and n-PA* was administered 12 to 24 hours after surgery. Therapy with rt-PA was withheld if there was evidence of postoperative hematoma or abnormalities in the coagulation profile. In addition, the dosage of rt-PA was reduced to 5 mg; continued minor bleeding complications and the results of serial measurements of t-PA in the cisternal CSF in the next four patients led to an additional revision of the pro- tocol. The dosage of rt-PA was reduced to 1.5 mg given in three equally divided dosages of 0.5 mg at 8-hour intervals in the next five patients. Neurological and physical examination and coagulation profiles were repeated before each dose was administered. Further treatment with rt-PA was withheld if there was clinical or laboratory evidence of coagulation abnormalities.
Serial ventricular and cisternal CSF samples were obtained after rt-PA administration. The CSF samples were placed on ice and transported immediately to the laboratory where they were centrifuged and the decanted fluid was stored at -70~ Samples were kept frozen until they were thawed in the central coagulation laboratory im mediately before performance of the t-PA assay. The t-PA antigen levels were measured with an enzyme-linked immunosorbent assay based on three murine monoclonal antibodies. ~ A detailed neurological examination was performed at the patient's admission to the study protocol and again at 1 and 3 months using the Cincinnati Stroke Scale, 2 and daily neurological examinations were performed during the first 14 days after hemorrhage using an abbreviated version of this stroke scale (Table 2 ). This grading scale, which is also known as the NIH Stroke Scale, has been extensively evaluated and validated in stroke patients and has been shown to have excellent correlation with CT findings. 2 A decline of two or more points on the abbreviated scale required evaluation of the patient to determine the reason for the change. Outcome at 1 and 3 months was assessed using the Glasgow Outcome Scale (Table 3) .m Computerized tomography was repeated t 2 to 24 hours after the administration of rt-PA and again 7 to 8 days after aneurysm rupture to rule out hemorrhagic complications. The effect of treatment with rt-PA on delayed arterial spasm was documented by follow-up angiography 7 to 9 days after aneurysmal hemorrhage, on which both the severity and distribution of arterial spasm were noted. Vasospasm was graded as severe if angiographic vessel luminal narrowing was greater than 50% of its original diameter, moderate for 30% to 50% narrowing, and mild for less than 30% reduction. Yranscranial Doppler ultrasound (TCD) studies were performed three times per week and the results were correlated with the clinical and radiographic findings. 
Results

Complications
Overall, there were no serious complications related to intracisternal therapy with rt-PA. There was no evidence of any systemic effect of serial coagulation parameters. Local abnormalities in coagulation were apparent in patients receiving rt-PA in doses of 5 or 10 rag. Oozing from the operative incision occurred in four patients and from the ventriculostomy site in two patients. Temporary, increases in bloody ventriculostomy drainage occurred during the first 8 to 16 hours after rt-PA administration in two patients and raised concerns of active intracranial bleeding. However, only one patient developed a small extra-axial hematoma (Fig. 2) which was treated by delayed burr-hole drainage. There were no apparent local or systemic effects on coagulation in the patients receiving a total dosage of 1.5 mg rt-PA in three divided doses.
Evidence qf Cerebral Vasospasm
Follow-up angiography 7 to 9 days after hemorrhage revealed mild to moderate spasm in nine of the I0 patients (Table 1 and Fig. 3 ). In the remaining patient, angiography revealed severe focal spasm involving the vertebral arteries bilaterally (Fig. 4) with mild to moderate spasm in the remaining vascular distributions. Serial TCD studies, available in eight of 10 patients, revealed maximum flow velocities of 110 to 180 cm/ sec (mean 148 cm/sec) in the middle cerebral artery and 90 to 164 cm/sec (mean 121 cm/sec) in the anterior cerebral artery, distribution during the first 2 weeks after SAH. Vertebral artery. TCD velocities could not be obtained for the patient with the posterior circulation aneurysm.
Clinical Outcome
Outcome was assessed 3 months following hemorrhage using the Glasgow Outcome Scale (Tables 1 and  3 ). t~ Six patients had good outcomes and were totally independent. Two patients bad moderate disability; these included an 83-year-old woman classified on admission as Hunt and Hess Grade III? and a 36-yearold man classified on admission as Hunt and Hess Grade IV.
There were two deaths. One patient, a 77-year-old woman, initially did well, but died 9 weeks after hemorrhage secondary to delayed pulmonary complications. Angiography 8 days after hemorrhage demonstrated only mild spasm (Fig. 3) . There was no evidence of ischemic injury on follow-up CT scans. The second patient, a 78-year-old woman, died secondary to pneumonia 6 weeks after hemorrhage. This patient had a history of severe atherosclerotic vascular disease, previous stroke, depression, and mild dementia. Her neurological status gradually declined following surgery and, despite evidence of only mild to moderate spasm on follow-up angiography, her CT scans obtained 2 weeks after hemorrhage demonstrated evidence of new infarcts.
Serial t-PA Levels
The results of serial t-PA assays for the four patients receiving a single 5-rag dose of rt-PA and for the five patients receiving a total dosage of 1.5 mg are presented in Table 4 . The CSF samples obtained at 0, 8, and 16 hours in the multiple dose regimen were drawn immediately prior to rt-PA administration. Levels of t-PA in the ventricular CSF were consistently lower than those obtained from the cisternal CSF. 
Discussion
Risk Factors.fi~r Vaso,v~asm
Despite extensive research, complications related to delayed cerebral vasospasm remain the major cause of morbidity and mortality in patients surviving aneurysreal SAH. The optimum method of managing vasospasm would be to prevent its occurrence. While the exact mechanism responsible for vasospasm is uncertain, there is little doubt that blood in the subarachnoid most invariably (23 of 24 cases). Other authors have reported similar correlations, suggesting that it is possible to identify the majority of patients at high risk for clinical vasospasm by CT criteria. ~:Ta Clinical grade and severity of hemorrhage are closely related. Results from a number of studies suggest that poor-grade patients have a higher risk of vasospasm. In the recently published Canadian trial of nimodipine in poor-grade aneurysm patients (in Hunt and Hess Grades lII to V), vasospasm complicated the hospital course of 36% of the nimodipine-treated patients and 56% of the placebo group. '~ These results can be compared with those of the nimodipine study conducted by Allen. et al.,' in ncurologically intact patients (in Hunt and Hess Grade I or II); in that study, ischemic deficits secondary to vasospasm were reported in 22% of the nimodipine-treated group and 26% of the control group, t
Removal o J" Subarachnoid Blood
In 1977, Osaka j~ suggested that, if vasospasm is produced by the components or breakdown products of blood, then it should be prevented by the removal of blood from the subarachnoid spaces. In fact, a possible role for the removal of blood from the cerebral cisterns to prevent vasospasm was first suggested by Johnson, et al., ~ in 1958 and by Pool '~ in 1959.
A number of authors have reported encouraging results from combining early surgical clipping of ruptured aneurysms with aggressive mechanical removal of blood from the basal cisterns.'5-~~ Saito and Sano 2~ reported reduction in symptomatic vasospasm from 42% of patients undergoing surgery between 4 and 8 days after SAH to 32% in a group that had surgery during the first 3 days with removal of subarachnoid clot. Taneda -'4 reduced delayed ischemic deficits that caused disability or death from 25% in patients who underwent surgery 10 or more days after hemorrhage to 11% in those undergoing surgery' with extensive removal of subarachnoid blood within 48 hours of hemorrhage. In laboratory models of SAH, there is clear evidence that early mechanical removal of blood from the subarachnoid spaces can prevent delayed cerebral vasospasm. 7'6 Nevertheless, general clinical experience with attempts at mechnical removal of blood has been disappointing.
Clinically, mechanical removal of clotted blood is usually limited by the operative exposure and can only be accomplished with some bruising of the pial surface and damage to small vessels. A more attractive theoretical alternative for the removal of subarachnoid blood is the use of fibrinolytic agents such as urokinase or rt-PA to enhance the natural clearing of blood.
The results of laboratory studies with rt-PA for the prevention of vasospasm have been encouraging. Using a primate model, Findlay, et al., [3] [4] [5] convincingly demonstrated that treatment with intracisternal rt-PA within 24 to 48 hours of SAH prevented angiographically significant delayed cerebral vasospasm. However, delaying treatment with rt-PA for 72 hours did not prevent spasm. 4 In the dog, Seifert, etal., 2~ have likewise demonstrated that treatment with rt-PA within 48 hours of SAH can prevent angiographic evidence of delayed cerebral vasospasm.
Pharmacology of rt-PA
Since its introduction, rt-PA has seen extensive clinical use for treatment of acute coronary thrombosis. More recently, attention has been directed to its possible use in treatment of acute stroke. In the peripheral circulation, the pharmacology of rt-PA has been well studied. Its metabolism after intra-arterial or intravenous administration is extremely rapid with a half-life of only 5 to 8 minutes. ' In their studies, rt-PA was given as a combination of a 1-mg/ml solution and a slow-release gel suspension. Sealing this dose up for clinical use, we estimated that a dose between 5 and 15 mg would be required to clear blood from the subarachnoid spaces of a patient with a Fisher Group 3 SAH.
The results of the present study demonstrate that rt-PA can be administered in the subarachnoid space with relative safety after the surgical clipping of a ruptured aneurysm. However, the occurrence of local bleeding complications in patients after rt-PA doses of 5 mg (four cases) or 10 mg (one case) suggests that the initial dosage chosen for evaluation was too high. The results of I-PA level assays in the cisternal CSF confirm this impression: t-PA levels averaged 42,000 ng/ml at 6 hours after a single 5-rag dose compared with a therapeutic range of 600 to 6000 ng/ml reported during systemic fibrinolysis. 2-~23
Mean t-PA levels in the cisternal CSF over time are presented graphically in Fig. 5 for those patients who received the single 5-mg dose of rt-PA. The shape of this curve suggests that degradation of t-PA in the CSF follows simple first-order kinetics. Calculations based on this assumption suggest that the half-life of rt-PA in CSF is 2 to 3 hours, which is markedly prolonged compared to the 5 to 8 minutes reported in the systemic circulation.
To maximize safety and yet assure adequate thrombolytic levels of t-PA in the CSF, the protocol was modified using smaller doses and interval administration. A total dosage of 1.5 mg of rt-PA (three intracisternal infusions of 0.5 mg every, 8 hours) was well tolerated without evidence of local or systemic bleeding complications. Cisternal t-PA levels averaged 11,856 ng/ml at 8 hours after the first dose and 17,377 ng/ml at 8 hours after the third dose, suggesting that even further reductions in dosage may be possible. Indeed, Seifert, et al., 2~ recently reported that a single dose of 0.025 mg rt-PA effectively cleared blood and prevented delayed cerebral vasospasm in a two-hemorrhage canine model. Unfortunately, t-PA levels in the CSF have not been measured in any of the published laboratory studies evaluating intracisternal therapy with rt-PA.
Ventricular levels of t-PA (Table 4) were consistently lower than those in the cisternal CSF, reflecting the local binding of t-PA to fibrin in the clotted blood in the subarachnoid space and dilution by the active production of CSF in the ventricular space. Levels varied by as much as 2 factors of 113. The results clearly demonstrate that ventficular levels of t-PA cannot be used to monitor cisternal enzyme activity.
Severity (?]" A ngiographic Vasospasm
Preliminary experience with rt-PA in this protocol suggests that it may reduce the severity of delayed cerebral vasospasm. Patients were chosen for this protocol on the basis of factors known to be associated with a high risk of clinical and angiographic vasospasm (poor clinical grade and evidence of a large hemorrhage on CT scans). The scale used to measure the severity of angiographic spasm in this protocol is the same as that used by Petruk, et al., ~ in the Canadian trial of nimodipine in poor-grade aneurysm patients, in which severe diffuse vasospasm was reported in 48% of the nimodipine-treated group and 56% in the placebotreated group. Follow-up angiography 7 to 9 days after hemorrhage in the present study demonstrated severe focal vasospasm in only one of 10 patients and mild to moderate spasm in the remaining nine (Table 1) . None of the patients had angiographic evidence of severe diffuse spasm.
There was no evidence that the effect of rt-PA was localized to the surgically dissected cisterns or influenced by the position of the cisternal catheter. This was true even for the patient with the posterior inferior cerebellar artery aneurysm in which the catheter was positioned adjacent to the left lateral aspect of the brain stem. This may be due in part to the high concentrations of rt-PA obtained in the present study. At lower doses, local binding of the drug to fibrin (for which it has a very high affinity) may prevent free diffusion through the subarachnoid cisterns.
Clinical Outcome
At the 3-month follow-up evaluation, 60% of the patients in the present protocol had "good" outcomes, 20% were "moderately disabled," and 20% had died. These results compare favorably with those reported in the clinical nimodipine trial by Petruk, etal., '~ cited above, in which patients admitted in Grade lII (Hunt and Hess scale) had a 44% "good" outcome while 28% died. While no conclusions regarding the efficacy of rt-PA can be made from such a comparison, it does provide evidence that treatment was not detrimental.
Conclusions
The results of this Phase I trial demonstrate that rt-PA can be administered in the subarachnoid space with relative safety in patients with aneurysmal SAH following definitive surgical clipping of the ruptured aneurysm and suggest that early treatment with rt-PA may reduce the severity of delayed angiographic vasospasm. Data from serial cisternal t-PA levels suggest that future investigations should evaluate lower-dosage regimens. Certainly, further studies are indicated.
